Abstract
The HMG-CoA reductase inhibitors (known as statins) have been shown to reduce morbi-mortality of vascular origin, including transitory ischemic accidents and cerebral infarcts, in a large group of patients. The implications, both clinical and of costs, oblige us to consider analysis of the existing evidence and the answers to a number of questions arising in a field which has not yet received much attention from neurologists.
MeSH terms
-
Adult
-
Arteriosclerosis / etiology
-
Arteriosclerosis / prevention & control
-
Cerebrovascular Disorders / epidemiology
-
Cerebrovascular Disorders / etiology
-
Cerebrovascular Disorders / prevention & control*
-
Cholesterol / blood
-
Clinical Trials as Topic
-
Drug Evaluation
-
Female
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
-
Hypercholesterolemia / complications
-
Hypercholesterolemia / drug therapy*
-
Ischemic Attack, Transient / epidemiology
-
Ischemic Attack, Transient / etiology
-
Ischemic Attack, Transient / prevention & control
-
Lipoproteins, HDL / blood
-
Lipoproteins, LDL / blood
-
Lovastatin / therapeutic use*
-
Male
-
Middle Aged
-
Pravastatin / therapeutic use*
-
Risk Factors
-
Simvastatin / therapeutic use*
-
Triglycerides / blood
Substances
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Lipoproteins, HDL
-
Lipoproteins, LDL
-
Triglycerides
-
Cholesterol
-
Lovastatin
-
Simvastatin
-
Pravastatin